Intensive HTN Treatment Cuts Early T2D Diagnosis-Linked CVD Event Risk
By Elana Gotkine HealthDay Reporter
MONDAY, April 29, 2024 -- More intensive hypertensive therapy significantly reduces the excess risk for cardiovascular disease (CVD) events associated with earlier hypertension diagnosis in women, but not men, with type 2 diabetes, according to a study published online April 24 in Diabetes Care.
Hongwei Ji, M.B.B.S., Ph.D., from Tsinghua University in Beijing, and colleagues analyzed intensive versus standard blood pressure control in relation to incident CVD events among women and men with type 2 diabetes based on age of diagnosis of hypertension. Data were included for 3,792 adults with type 2 diabetes (49 percent women).
The researchers found an increased risk for CVD per decade earlier age at hypertension diagnosis (hazard ratio, 1.11). In women, but not men, the excess risk associated with early-diagnosed hypertension was attenuated in the presence of intensive versus standard hypertension therapy.
"Given the potential clinical implications of our findings, additional work is needed to validate our results in separate prospective studies as well as examine underlying mechanisms that could be further targeted as part of efforts to reduce the residual excess CVD risk in women with type 2 diabetes," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Causal Relationship Seen Between GERD and Hypertension
WEDNESDAY, Oct. 30, 2024 -- There is a positive causal relationship between gastroesophageal reflux disease (GERD) and hypertension, according to a study published online Sept. 23...
ASN: Hypertension Most Common Cardiovascular Comorbidity Seen With Dialysis
WEDNESDAY, Oct. 30, 2024 -- Hypertension is the most common cardiovascular disease (CVD) comorbidity seen among dialysis patients globally, according to a study presented at...
Small but Important Differences Seen Between Rosuvastatin, Atorvastatin
WEDNESDAY, Oct. 30, 2024 -- There are small but important differences in risk for some clinical outcomes associated with rosuvastatin and atorvastatin, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.